Evidence map›Paper›PMID 39236689›Full record

ArticleACS nano2024

Spatial Measurement and Inhibition of Calpain Activity in Traumatic Brain Injury with an Activity-Based Nanotheranostic Platform.

Marianne I Madias, Lilyane N Stessman, Sophia J Warlof, Julia A Kudryashev, Ester J Kwon

Abstract read
In one paragraph

Article in ACS nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Aloin attenuates NMDA receptor by modulating calcium response on substantia gelatinosa neurons of the trigeminal subnucleus caudalis in mice.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marianne I MadiasDepartment of Bioengineering, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0003-0127-7952
Lilyane N StessmanDepartment of Bioengineering, University of California, San Diego, La Jolla, California 92093, United States.
Sophia J WarlofDepartment of Bioengineering, University of California, San Diego, La Jolla, California 92093, United States.
Julia A KudryashevDepartment of Bioengineering, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0003-3022-0058
Ester J KwonDepartment of Bioengineering, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-6335-9681

Funding

Nanoscale Biomaterials for Targeted Repair in Traumatic Brain InjuryDP2NS111507 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KWON, ESTER J. · 2018 to 2018
$2.4M
Training in Bioengineering Research and Technology Development in Cardiovascular in Cardiopulmonary Health and DiseaseT32HL160507 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Karen L Christman, Andrew D. McCulloch · 2022 to 2026
$1.6M
NHLBI NIH HHS T32 HL160507NINDS NIH HHS DP2 NS111507
6 · The paper itself

Abstract

Traumatic brain injury (TBI) is a major public health concern that can result in long-term neurological impairments. Calpain is a calcium-dependent cysteine protease that is activated within minutes after TBI, and sustained calpain activation is known to contribute to neurodegeneration and blood-brain barrier dysregulation. Based on its role in disease progression, calpain inhibition has been identified as a promising therapeutic target. Efforts to develop therapeutics for calpain inhibition would benefit from the ability to measure calpain activity with spatial precision within the injured tissue. In this work, we designed an activity-based nanotheranostic (ABNT) that can both sense and inhibit calpain activity in TBI. To sense calpain activity, we incorporated a peptide substrate of calpain flanked by a fluorophore/quencher pair. To inhibit calpain activity, we incorporated calpastatin peptide, an endogenous inhibitor of calpain. Both sensor and inhibitor peptides were scaffolded onto a polymeric nanoscaffold to create our ABNT. We show that in the presence of recombinant calpain, our ABNT construct is able to sense and inhibit calpain activity. In a mouse model of TBI, systemically administered ABNT can access perilesional brain tissue through passive accumulation and inhibit calpain activity in the cortex and hippocampus. In an analysis of cellular calpain activity, we observe the ABNT-mediated inhibition of calpain activity in neurons, endothelial cells, and microglia of the cortex. In a comparison of neuronal calpain activity by brain structure, we observe greater ABNT-mediated inhibition of calpain activity in cortical neurons compared to that in hippocampal neurons. Furthermore, we found that apoptosis was dependent on both calpain inhibition and brain structure. We present a theranostic platform that can be used to understand the regional and cell-specific therapeutic inhibition of calpain activity to help inform drug design for TBI.

Indexed as

Brain Injuries, TraumaticCalpainAnimalsHumansMaleMiceMice, Inbred C57BLPeptidesCalpainPeptidesactivity-based nanosensorcalpastatincontrolled cortical impactpolyethylene glycolTUNEL

Identifiers

PMID39236689
PMCPMC11411711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.